Cargando…

Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion

Cutaneous squamous cell carcinoma (CSCC) is the second most common skin malignancy in white-skinned populations. Only a minority of patients (<5%) develop advanced disease, but this is often difficult to treat and characterised by a poor prognosis. Cemiplimab, a fully human IgG4 monoclonal antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Argenziano, Giuseppe, Fargnoli, Maria Concetta, Fantini, Fabrizio, Gattoni, Massimo, Gualdi, Giulio, Pastore, Francesco, Pellacani, Giovanni, Quaglino, Pietro, Queirolo, Paola, Troiani, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753075/
https://www.ncbi.nlm.nih.gov/pubmed/35035534
http://dx.doi.org/10.1177/17588359211066272
_version_ 1784632014536704000
author Argenziano, Giuseppe
Fargnoli, Maria Concetta
Fantini, Fabrizio
Gattoni, Massimo
Gualdi, Giulio
Pastore, Francesco
Pellacani, Giovanni
Quaglino, Pietro
Queirolo, Paola
Troiani, Teresa
author_facet Argenziano, Giuseppe
Fargnoli, Maria Concetta
Fantini, Fabrizio
Gattoni, Massimo
Gualdi, Giulio
Pastore, Francesco
Pellacani, Giovanni
Quaglino, Pietro
Queirolo, Paola
Troiani, Teresa
author_sort Argenziano, Giuseppe
collection PubMed
description Cutaneous squamous cell carcinoma (CSCC) is the second most common skin malignancy in white-skinned populations. Only a minority of patients (<5%) develop advanced disease, but this is often difficult to treat and characterised by a poor prognosis. Cemiplimab, a fully human IgG4 monoclonal antibody against programmed cell death-1 receptor, is indicated for advanced (i.e. locally advanced or metastatic) CSCC. Although the definition of metastatic CSCC is clear, there is currently no agreed definition of locally advanced CSCC. In recent guidelines, locally advanced CSCC was described as non-metastatic CSCC that is unlikely to be cured with surgery, radiotherapy or combination treatment. A multi-disciplinary advisory group of Italian CSCC experts was convened to develop criteria to assist in identifying appropriate candidates for cemiplimab therapy in advanced CSCC, based on the literature and clinical experience. In locally advanced CSCC, absolute, or mandatory, criteria for the use of cemiplimab are deep invasion, multiple lesions without defined margins, inadequate surgical excision margins and multiple recurrences, whereas relative criteria include large lesions, in critical or functionally significant areas and that are surgically complex. In addition, physicians should consider patient willingness/preferences (an absolute criterion), and their age and health status/comorbidities (relative criteria). It is hoped that these proposed absolute and relative criteria will help guide rational identification of patients who will receive maximum benefit from immunotherapy, while more clinical data accumulate.
format Online
Article
Text
id pubmed-8753075
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-87530752022-01-13 Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion Argenziano, Giuseppe Fargnoli, Maria Concetta Fantini, Fabrizio Gattoni, Massimo Gualdi, Giulio Pastore, Francesco Pellacani, Giovanni Quaglino, Pietro Queirolo, Paola Troiani, Teresa Ther Adv Med Oncol Review Cutaneous squamous cell carcinoma (CSCC) is the second most common skin malignancy in white-skinned populations. Only a minority of patients (<5%) develop advanced disease, but this is often difficult to treat and characterised by a poor prognosis. Cemiplimab, a fully human IgG4 monoclonal antibody against programmed cell death-1 receptor, is indicated for advanced (i.e. locally advanced or metastatic) CSCC. Although the definition of metastatic CSCC is clear, there is currently no agreed definition of locally advanced CSCC. In recent guidelines, locally advanced CSCC was described as non-metastatic CSCC that is unlikely to be cured with surgery, radiotherapy or combination treatment. A multi-disciplinary advisory group of Italian CSCC experts was convened to develop criteria to assist in identifying appropriate candidates for cemiplimab therapy in advanced CSCC, based on the literature and clinical experience. In locally advanced CSCC, absolute, or mandatory, criteria for the use of cemiplimab are deep invasion, multiple lesions without defined margins, inadequate surgical excision margins and multiple recurrences, whereas relative criteria include large lesions, in critical or functionally significant areas and that are surgically complex. In addition, physicians should consider patient willingness/preferences (an absolute criterion), and their age and health status/comorbidities (relative criteria). It is hoped that these proposed absolute and relative criteria will help guide rational identification of patients who will receive maximum benefit from immunotherapy, while more clinical data accumulate. SAGE Publications 2022-01-09 /pmc/articles/PMC8753075/ /pubmed/35035534 http://dx.doi.org/10.1177/17588359211066272 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Argenziano, Giuseppe
Fargnoli, Maria Concetta
Fantini, Fabrizio
Gattoni, Massimo
Gualdi, Giulio
Pastore, Francesco
Pellacani, Giovanni
Quaglino, Pietro
Queirolo, Paola
Troiani, Teresa
Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
title Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
title_full Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
title_fullStr Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
title_full_unstemmed Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
title_short Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
title_sort identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753075/
https://www.ncbi.nlm.nih.gov/pubmed/35035534
http://dx.doi.org/10.1177/17588359211066272
work_keys_str_mv AT argenzianogiuseppe identifyingcandidatesforimmunotherapywithcemiplimabtotreatadvancedcutaneoussquamouscellcarcinomaanexpertopinion
AT fargnolimariaconcetta identifyingcandidatesforimmunotherapywithcemiplimabtotreatadvancedcutaneoussquamouscellcarcinomaanexpertopinion
AT fantinifabrizio identifyingcandidatesforimmunotherapywithcemiplimabtotreatadvancedcutaneoussquamouscellcarcinomaanexpertopinion
AT gattonimassimo identifyingcandidatesforimmunotherapywithcemiplimabtotreatadvancedcutaneoussquamouscellcarcinomaanexpertopinion
AT gualdigiulio identifyingcandidatesforimmunotherapywithcemiplimabtotreatadvancedcutaneoussquamouscellcarcinomaanexpertopinion
AT pastorefrancesco identifyingcandidatesforimmunotherapywithcemiplimabtotreatadvancedcutaneoussquamouscellcarcinomaanexpertopinion
AT pellacanigiovanni identifyingcandidatesforimmunotherapywithcemiplimabtotreatadvancedcutaneoussquamouscellcarcinomaanexpertopinion
AT quaglinopietro identifyingcandidatesforimmunotherapywithcemiplimabtotreatadvancedcutaneoussquamouscellcarcinomaanexpertopinion
AT queirolopaola identifyingcandidatesforimmunotherapywithcemiplimabtotreatadvancedcutaneoussquamouscellcarcinomaanexpertopinion
AT troianiteresa identifyingcandidatesforimmunotherapywithcemiplimabtotreatadvancedcutaneoussquamouscellcarcinomaanexpertopinion